ArticlePsychiatry investigation2025
The Association of Zolpidem and Suicidality in Psychiatric Outpatients With Insomnia.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveZolpidem is widely prescribed to psychiatric outpatients for the management of insomnia due to its rapid and potent efficacy. However, concerns persist regarding its potential association with suicidal tendencies. While studies have suggested that Z-drugs may influence suicidal behavior in the general population, the specific association of Z-drug use and suicide risk in psychiatric outpatients with insomnia remains unclear. This study aims to investigate the association of zolpidem use and suicidal tendencies in this population.
methodsThis retrospective study analyzed the medical records of psychiatric outpatients who visited a mental health clinic between January 2018 and December 2022. Of the 6,193 patients assessed, 3,128 (average age: 49.4 years; 36.6% male) reported insomnia, and 364 (11.6%) were prescribed zolpidem. Suicidal tendencies including past suicide attempts, current suicidal ideation, and plans were evaluated in relation to zolpidem use.
resultsPsychiatric outpatients with insomnia who used zolpidem demonstrated significantly higher rates of suicidal tendencies (χ2=3.97, p=0.046) and suicide attempts (χ2=8.12, p=0.004, 23.6% in zolpidem users) compared to non-users. Logistic regression analysis revealed that zolpidem use was significantly associated with increased suicidal tendencies (β=0.314, standard error=0.137, odds ratio= 1.368, 95% confidence interval [CI] 1.05-1.79, p=0.022), suicidal ideation (β=0.326, standard error=0.138, odds ratio=1.386, 95% CI 1.06-1.82, p=0.018), and suicide attempts (β=0.379, standard error=0.157, odds ratio=1.460, 95% CI 1.07-1.98, p=0.016), even after adjusting for relevant clinical factors.
conclusionThis study highlights a significant association of zolpidem use and elevated suicidal tendencies among psychiatric outpatients with insomnia. Although a causal relationship cannot be definitively established, these findings highlight the critical importance of thorough suicide risk assessment and ongoing monitoring in patients prescribed zolpidem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.